Ospedale Sandro Pertini

Futó vizsgálatok

• Toboroz

  A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

  NCT07073079· AbbVie· Forrás

• Toboroz

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· 2/3. fázis· CSL Behring· Forrás

• Fut, nem toboroz

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· 3. fázis· Eli Lilly and Company· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Crohn-betegség1 toboroz
• Koszorúér-betegség1 toboroz
• Krónikus vesebetegség1 toboroz
• Peripheral artery disease1 toboroz

Lezárt vizsgálatok

• Lezárult

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· 2. fázis· Amgen Inc.· Forrás

• Lezárult

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· 3. fázis· Bayer AG· Forrás

• Lezárult

  Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis

  NCT04987307· 2. fázis· Amgen Inc.· Forrás

• Lezárult

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· 3. fázis· Eli Lilly and Company· Forrás

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Thalassaemia6 munka · 0 vizsgálat